As this subtype lacks the three main breast cancer molecular biomarkers (estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)), there are no targeted therapy options for TNBC, and the use of conventional chemotherapies remains the standard of care. This evidence concerns the gene PGR and breast cancer.